Meeting
2013 ASCO Annual Meeting
Bevacizumab (Bev) for treatment of recurrent serous borderline (SB) or low-grade serous (LGS) ovarian cancer: A retrospective review of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience.
Authors
Rachel N. Grisham
Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY
Rachel N. Grisham , Evis Sala , Qin Zhou , Alexia Iasonos , Deborah DeLair , Gopa Iyer , David Michael Hyman , David R. Spriggs , Carol Aghajanian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 5545)
DOI
10.1200/jco.2013.31.15_suppl.5545
Abstract #
5545
Poster Bd #
45A
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase 2 study.
First Author: Ursula A. Matulonis
Poster
2024 ASCO Annual Meeting
Tisotumab vedotin in 2L/3L recurrent or metastatic cervical cancer: Subsequent therapy data from ENGOT-cx12/GOG-3057/innovaTV 301.
First Author: Luis Manso
Poster
2022 ASCO Annual Meeting
PERCEPTION: Phase II investigational study of pembrolizumab combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer— A NOGGO trial.
First Author: Jacek P. Grabowski
Poster
2021 ASCO Annual Meeting
Tisotumab vedotin versus investigator’s choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT‑cx12/GOG 3057, trial in progress).
First Author: Ignace Vergote